Sign up for Table of Contents Alerts.
Cell Cycle is published 24 times a year.
Email this page
Print this page
Spotlight on HIF
Targeting Topoisomerase 1 to inhibit Hypoxia Inducible Factor 1
Annamaria Rapisarda, Robert H. Shoemaker, and Giovanni Melillo
volume 3 | issue 2
Feb 2004Pages: 172-175
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDF If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.
HIF-1 is a key factor in cancer progression. Efforts are underway to identify and develop small molecules that inhibit HIF-1 transcriptional activity. What are the best targets and the best ways to develop HIF-1 inhibitors are open questions. However, several “non-selective” HIF-1 inhibitors have been identified, which are either in the clinic or under development. In this article, we discuss how topoisomerase 1 poisons, which inhibit HIF-1a protein accumulation and transcriptional activity, can be “rationally” used to target HIF-1 for cancer therapy.
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDF If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.